{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T01:34:09Z","timestamp":1772847249383,"version":"3.50.1"},"reference-count":113,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":584,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1002\/rth2.12527","type":"journal-article","created":{"date-parts":[[2021,5,9]],"date-time":"2021-05-09T04:27:25Z","timestamp":1620534445000},"page":"e12527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Micronized purified flavonoid fraction for the treatment of chronic venous insufficiency, with a focus on postthrombotic syndrome: A narrative review"],"prefix":"10.1016","volume":"5","author":[{"given":"Ke Xuan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisele","family":"Diend\u00e9r\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean\u2010Philippe","family":"Galanaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nada","family":"Mahjoub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5667-8916","authenticated-orcid":false,"given":"Susan R.","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1002\/rth2.12527_bb0010","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.thromres.2018.02.005","article-title":"Special issue: Late consequences of venous thromboembolism","volume":"164","author":"Kahn","year":"2018","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12527_bb0015","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.thromres.2017.07.026","article-title":"Epidemiology of the post\u2010thrombotic syndrome","volume":"164","author":"Galanaud","year":"2018","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12527_bb0020","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1160\/TH16-02-0152","article-title":"What is the effect of venous thromboembolism and related complications on patient reported health\u2010related quality of life? A meta\u2010analysis","volume":"116","author":"Lubberts","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1002\/rth2.12527_bb0025","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1600-0609.2011.01733.x","article-title":"Healthcare burden associated with the post\u2010thrombotic syndrome and potential impact of the new oral anticoagulants","volume":"88","author":"Prandoni","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1002\/rth2.12527_bb0030","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1016\/S2352-3026(15)00248-3","article-title":"Post\u2010thrombotic syndrome after catheter\u2010directed thrombolysis for deep vein thrombosis (CaVenT): 5\u2010year follow\u2010up results of an open\u2010label, randomised controlled trial","volume":"3","author":"Haig","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1002\/rth2.12527_bb0035","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMoa1615066","article-title":"Pharmacomechanical catheter\u2010directed thrombolysis for deep\u2010vein thrombosis","volume":"377","author":"Vedantham","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12527_bb0040","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/S2352-3026(19)30209-1","article-title":"Ultrasound\u2010accelerated catheter\u2010directed thrombolysis versus anticoagulation for the prevention of post\u2010thrombotic syndrome (CAVA): a single\u2010blind, multicentre, randomised trial","volume":"7","author":"Notten","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1002\/rth2.12527_bb0045","first-page":"CD004174","article-title":"Compression therapy for prevention of post\u2010thrombotic syndrome","volume":"9","author":"Appelen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1002\/rth2.12527_bb0050","first-page":"CD004177","article-title":"Compression therapy for treating post\u2010thrombotic syndrome","volume":"9","author":"Azirar","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1002\/rth2.12527_bb0055","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1182\/blood-2018-01-785956","article-title":"How I treat the postthrombotic syndrome","volume":"131","author":"Rabinovich","year":"2018","journal-title":"Blood"},{"key":"10.1002\/rth2.12527_bb0060","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1055\/s-0036-1597756","article-title":"Management of varicose veins and chronic venous insufficiency in a comparative registry with nine venoactive products in comparison with stockings","volume":"26","author":"Belcaro","year":"2017","journal-title":"Int J Angiol"},{"key":"10.1002\/rth2.12527_bb0065","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ejvs.2015.02.007","article-title":"Editor's choice \u2010 management of chronic venous disease: clinical practice guidelines of the European Society for Vascular Surgery (ESVS)","volume":"49","author":"Wittens","year":"2015","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1002\/rth2.12527_bb0070","first-page":"CD003229","article-title":"Phlebotonics for venous insufficiency","volume":"4","author":"Martinez\u2010Zapata","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1002\/rth2.12527_bb0075","first-page":"81","article-title":"Different flavonoids present in the micronized purified flavonoid fraction (Daflon 500 mg) contribute to its anti\u2010hyperpermeability effect in the hamster cheek pouch microcirculation","volume":"27","author":"Paysant","year":"2008","journal-title":"Int Angiol"},{"issue":"2","key":"10.1002\/rth2.12527_bb0080","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.amjms.2018.03.004","article-title":"Postthrombotic syndrome: long\u2010term sequela of deep venous thrombosis","volume":"356","author":"Moustafa","year":"2018","journal-title":"Am J Med Sci"},{"key":"10.1002\/rth2.12527_bb0085","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000179096","article-title":"An original microhaemorheological approach to the pharmacological effects of Daflon 500 mg in severe chronic venous insufficiency","volume":"15","author":"Allegra","year":"1995","journal-title":"Int J Microcirc Clin Exp"},{"issue":"suppl 1","key":"10.1002\/rth2.12527_bb0090","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000179095","article-title":"Laser Doppler and transcutaneous oximetry: modern investigations to assess drug efficacy in chronic venous insufficiency","volume":"15","author":"Belcaro","year":"1995","journal-title":"Int J Microcirc Clin Exp"},{"key":"10.1002\/rth2.12527_bb0095","first-page":"69","article-title":"A double\u2010blind, placebo\u2010controlled trial of a new veno\u2010active flavonoid fraction (S 5682) in the treatment of symptomatic capillary fragility","volume":"12","author":"Galley","year":"1993","journal-title":"Int Angiol"},{"key":"10.1002\/rth2.12527_bb0100","first-page":"35","article-title":"Study of capillary filtration by double labelling I131\u2010albumin and Tc99m red cells. Application to the pharmacodynamic activity of Daflon 500 mg","volume":"7","author":"Behar","year":"1988","journal-title":"Int Angiol"},{"key":"10.1002\/rth2.12527_bb0105","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1177\/000331979704800503","article-title":"Effects of oral administration of purified micronized flavonoid fraction on increased microvascular permeability induced by various agents and on ischemia\/reperfusion in the hamster cheek pouch","volume":"48","author":"Bouskela","year":"1997","journal-title":"Angiology"},{"key":"10.1002\/rth2.12527_bb0110","first-page":"12","article-title":"Microlymphography: assessment of Daflon 500 mg activity in patients with chronic venous insufficiency","volume":"31","author":"Allegra","year":"1997","journal-title":"Lymphology"},{"key":"10.1002\/rth2.12527_bb0115","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/000331970005100105","article-title":"Pharmacologic aspects of a phlebotropic drug in CVI\u2010associated edema","volume":"51","author":"Ramelet","year":"2000","journal-title":"Angiology"},{"key":"10.1002\/rth2.12527_bb0120","first-page":"53","article-title":"Are the phlebotonic properties shown in clinical pharmacology predictive of a therapeutic benefit in chronic venous insufficiency? Our experience with Daflon 500 mg","volume":"8","author":"Tsouderos","year":"1989","journal-title":"Int Angiol"},{"key":"10.1002\/rth2.12527_bb0125","first-page":"32","article-title":"Activit\u00e9 th\u00e9rapeutique de Daflon 500 mg dans l\u2019insuffisance veineuse fonctionnelle","volume":"99","author":"Chassignolle","year":"1987","journal-title":"J Int Med"},{"key":"10.1002\/rth2.12527_bb0130","first-page":"41","article-title":"Pharmacodynamic properties and therapeutic efficacy of Daflon 500 mg","volume":"7","author":"Barbe","year":"1992","journal-title":"Phlebology"},{"key":"10.1002\/rth2.12527_bb0135","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/000331979704800108","article-title":"Venous elasticity after treatment with Daflon 500 mg","volume":"48","author":"Ibegbuna","year":"1997","journal-title":"Angiology"},{"key":"10.1002\/rth2.12527_bb0140","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s13126-017-0415-1","article-title":"Beneficial effect of MPFF administration on the healing process of venous ulcer","volume":"89","author":"Katseni","year":"2017","journal-title":"Hell J Surg"},{"key":"10.1002\/rth2.12527_bb0145","first-page":"18","article-title":"Great saphenous vein transitory reflux in patients with symptoms related to chronic venous disorders, but without visible signs (C0s), and its correction with MPFF treatment","volume":"22","author":"Tsoukanov","year":"2015","journal-title":"Phlebolymphology"},{"key":"10.1002\/rth2.12527_bb0150","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejvs.2007.08.011","article-title":"Mechanisms in experimental venous valve failure and their modification by Daflon 500 mg","volume":"35","author":"Pascarella","year":"2008","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1002\/rth2.12527_bb0155","first-page":"52","article-title":"[Ultrasound assessment of alterations in venous haemodynamics in patients with post\u2010thrombotic disease permanently taking phlebotonics]","volume":"20","author":"Zudin","year":"2014","journal-title":"Angiol Sosud Khir"},{"key":"10.1002\/rth2.12527_bb0160","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejvs.2005.04.017","article-title":"Venous leg ulcer: a meta\u2010analysis of adjunctive therapy with micronized purified flavonoid fraction","volume":"30","author":"Coleridge\u2010Smith","year":"2005","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1002\/rth2.12527_bb0165","first-page":"1902","article-title":"Venous leg ulcers","volume":"2011","author":"Nelson","year":"2011","journal-title":"BMJ Clin Evid"},{"key":"10.1002\/rth2.12527_bb0170","first-page":"32","article-title":"Activit\u00e9 th\u00e9rapeutique de Daflon 500 mg dans l\u2019insuffisance veineuse fonctionnelle","volume":"99","author":"Chassignolle","year":"1999","journal-title":"JIM"},{"key":"10.1002\/rth2.12527_bb0175","first-page":"45","article-title":"Stripping of the great saphenous vein under micronized purified flavonoid fraction (MPFF) protection (results of the Russian multicenter controlled trial DEFANCE)","volume":"15","author":"Saveuev","year":"2008","journal-title":"Phlebolymphology"},{"key":"10.1002\/rth2.12527_bb0180","first-page":"195","article-title":"Analysis of the various procedures used in great saphenous vein surgery in the Czech Republic and benefit of Daflon 500 mg to postoperative symptoms","volume":"13","author":"Veverkov\u00e1","year":"2006","journal-title":"Phlebolymphology"},{"key":"10.1002\/rth2.12527_bb0185","unstructured":"Maruszynski M. A double blind, randomized study evaluating the influence of semi\u2010synthetic diosmin, and a purified, micronized flavonoid fraction (diosmin and hesperidin), on symptoms of chronic venous insufficiency of the lower limb \u2013 a four\u2010week observation: http:\/\/sensoril.com\/wp\u2010content\/uploads\/2012\/11\/Maruszynski\u2010clinical\u2010trial\u2010Poland\u20102004\u2010English\u2010translation.pdf; 2004(accessed 15 December 2019)."},{"key":"10.1002\/rth2.12527_bb0190","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/000331970605700201","article-title":"Venoruton vs Daflon: evaluation of effects on quality of life in chronic venous insufficiency","volume":"57","author":"Cesarone","year":"2006","journal-title":"Angiology"},{"key":"10.1002\/rth2.12527_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/000331970505600101","article-title":"HR, 0\u2010(beta\u2010hydroxyethyl)\u2010rutosides, in comparison with diosmin+hesperidin in chronic venous insufficiency and venous microangiopathy: an independent, prospective, comparative registry study","volume":"56","author":"Cesarone","year":"2005","journal-title":"Angiology"},{"key":"10.1002\/rth2.12527_bb0200","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/026835559901400405","article-title":"The beneficial augmentative effect of micronised purified flavonoid fraction (MPFF) on the healing of leg ulcers: an open, multicentre, controlled, randomised study","volume":"14","author":"Gli\u00f1ski","year":"1999","journal-title":"Phlebology"},{"issue":"suppl 1","key":"10.1002\/rth2.12527_bb0205","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000179263","article-title":"Benefit of a 2\u2010month treatment with a micronized, purified flavonoidic fraction on venous ulcer healing. A randomized, double\u2010blind, controlled versus placebo trial","volume":"17","author":"Guilhou","year":"1997","journal-title":"Int J Microcirc Clin Exp"},{"issue":"suppl 7","key":"10.1002\/rth2.12527_bb0210","first-page":"95","article-title":"Venous tone: are the phlebotonic properties predictive of a therapeutic benefit? A comprehensive view of our experience with Daflon 500 mg","volume":"80","author":"Tsouderos","year":"1991","journal-title":"Z Kardiol"},{"key":"10.1002\/rth2.12527_bb0215","first-page":"36","article-title":"Activit\u00e9 th\u00e9rapeutique de Daflon 500 mg dans l\u2019insuffisance veineuse chronique des membres inf\u00e9rieurs","author":"Frileux","year":"1987","journal-title":"J Int M\u00e9d"},{"key":"10.1002\/rth2.12527_bb0220","first-page":"447","article-title":"Evaluation of a new micronized diosmin in the treatment of chronic venous incompetence: a double\u2010blind, placebo controlled trial","volume":"15","author":"Thiollet","year":"1992","journal-title":"J Vasc Surg"},{"key":"10.1002\/rth2.12527_bb0225","first-page":"32","article-title":"Activit\u00e9 th\u00e9rapeutique de Daflon 500 mg dans l'insuffisance veineuse fonctionnelle","volume":"99","author":"Chassignolle","year":"1994","journal-title":"J Int Med"},{"key":"10.1002\/rth2.12527_bb0230","first-page":"61","article-title":"Double blind study of the pharmacodynamic and clinical activities of 5682 SE in venous insufficiency. Advantages of the new micronized form","volume":"8","author":"Cospite","year":"1989","journal-title":"Int Angiol"},{"key":"10.1002\/rth2.12527_bb0235","first-page":"531","article-title":"Advantage of a micronized flavonoidic fraction (Daflon 500 mg) in comparison with a nonmicronized diosmin","volume":"45","author":"Amato","year":"1994","journal-title":"Angiology"},{"key":"10.1002\/rth2.12527_bb0240","first-page":"39","article-title":"Clinical evaluation of a venotropic drug in man. Example of Daflon 500 mg","volume":"7","author":"Laurent","year":"1988","journal-title":"Int Angiol"},{"key":"10.1002\/rth2.12527_bb0245","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/000331970005100107","article-title":"RELIEF study: first consolidated European data. Reflux assEssment and quaLity of lIfe improvement with micronized Flavonoids","volume":"51","author":"Jantet","year":"2000","journal-title":"Angiology"},{"key":"10.1002\/rth2.12527_bb0250","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/000331970205300301","article-title":"Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assEssment and quaLity of lIfe improvEment with micronized Flavonoids","volume":"53","author":"Jantet","year":"2002","journal-title":"Angiology"},{"key":"10.1002\/rth2.12527_bb0255","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/asheducation-2016.1.413","article-title":"The post\u2010thrombotic syndrome","volume":"2016","author":"Kahn","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1002\/rth2.12527_bb0260","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1053\/ejvs.1998.0751","article-title":"Endothelial activation response to oral micronised flavonoid therapy in patients with chronic venous disease\u2013a prospective study","volume":"17","author":"Shoab","year":"1999","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1002\/rth2.12527_bb0265","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s12325-018-0731-z","article-title":"Administration of micronized purified flavonoid fraction during sclerotherapy of reticular veins and telangiectasias: results of the national, multicenter, observational program VEIN ACT PROLONGED\u2010C1","volume":"35","author":"Bogachev","year":"2018","journal-title":"Adv Ther"},{"key":"10.1002\/rth2.12527_bb0270","first-page":"77","article-title":"[Efficacy of Venarus in treatment of patients with post\u2010thrombotic disease of lower limbs]","volume":"20","author":"Son'kin","year":"2014","journal-title":"Angiol Sosud Khir"},{"key":"10.1002\/rth2.12527_bb0275","doi-asserted-by":"crossref","first-page":"189","DOI":"10.23736\/S0392-9590.16.03708-1","article-title":"Orthostatic\u2010loading\u2010induced transient venous refluxes (day orthostatic loading test), and remedial effect of micronized purified flavonoid fraction in patients with telangiectasia and reticular vein","volume":"36","author":"Tsukanov","year":"2017","journal-title":"Int Angiol"},{"key":"10.1002\/rth2.12527_bb0280","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-0035-1570118","article-title":"Secondary varicose small pelvic veins and their treatment with micronized purified flavonoid fraction","volume":"25","author":"Tsukanov","year":"2016","journal-title":"Int J Angiol"},{"key":"10.1002\/rth2.12527_bb0285","first-page":"146","article-title":"Benefits of MPFF on primary chronic venous disease\u2010related symptoms and quality of life: the DELTA study","volume":"21","author":"Yanushko","year":"2014","journal-title":"Phlebolymphology"},{"key":"10.1002\/rth2.12527_bb0290","first-page":"90","article-title":"[Ultrasound elastography in assessing efficacy of treatment for lower limb varicose veins with a phlebotrophic drug containing a micronized purified flavonoid fraction]","volume":"20","author":"Zubarev","year":"2014","journal-title":"Angiol Sosud Khir"},{"key":"10.1002\/rth2.12527_bb0295","first-page":"79","article-title":"Benefit of Daflon 500 mg in the reduction of chronic venous disease\u2010related symptoms","volume":"19","author":"Lenkovic","year":"2012","journal-title":"Phlebolymphology"},{"key":"10.1002\/rth2.12527_bb0300","first-page":"137","article-title":"Efficacy of a 6\u2010month treatment with Daflon 500 mg* in patients with venous edema (Efficacy of Daflon 500 mg* in Edema Treatment. EDET)","volume":"17","author":"Navratilova","year":"2010","journal-title":"Phlebolymphology"},{"key":"10.1002\/rth2.12527_bb0305","first-page":"60","article-title":"[Microcirculation end effect of detralex in patients with chronic venous insufficiency of the lower extremities]","volume":"9","author":"Sirotin","year":"2003","journal-title":"Angiol Sosud Khir"},{"key":"10.1002\/rth2.12527_bb0310","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1177\/153857440103500604","article-title":"Clinical and hemodynamic outcomes in patients with chronic venous insufficiency after oral micronized flavonoid therapy","volume":"35","author":"Ting","year":"2001","journal-title":"Vasc Surg"},{"key":"10.1002\/rth2.12527_bb0315","first-page":"80","article-title":"[The drug therapy of chronic venous insufficiency (a trial of the clinical use of the preparation Detralex)]","volume":"68","author":"Iablokov","year":"1996","journal-title":"Ter Arkh"},{"key":"10.1002\/rth2.12527_bb0320","first-page":"37","article-title":"Quantification of oedema using the volometer technique: therapeutic application of Daflon\u00ae 500 mg in chronic venous insufficiency","author":"Blume","year":"1992","journal-title":"Phlebology"},{"key":"10.1002\/rth2.12527_bb0325","first-page":"67","article-title":"A long term treatment with a venotropic drug. Results on efficacy and safety of Daflon 500 mg in chronic venous insufficiency","volume":"8","author":"Guillot","year":"1989","journal-title":"Int Angiol"},{"key":"10.1002\/rth2.12527_bb0330","first-page":"97","article-title":"Open prospective randomized study of the results of using Venarus in postthrombotic disease","volume":"24","author":"Ignat'ev","year":"2018","journal-title":"Angiol Sosud Khir"},{"key":"10.1002\/rth2.12527_bb0335","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.avsg.2016.04.014","article-title":"Effect of pycnogenol on the healing of venous ulcers","volume":"38","author":"Toledo","year":"2017","journal-title":"Ann Vasc Surg"},{"key":"10.1002\/rth2.12527_bb0340","first-page":"90","article-title":"[On advisability of perioperative phleboprotection in endovascular treatment of lower in varicose disease: first initial results of the decision study]","volume":"18","author":"Bogachev","year":"2012","journal-title":"Angiol Sosud Khir"},{"key":"10.1002\/rth2.12527_bb0345","doi-asserted-by":"crossref","first-page":"402","DOI":"10.23736\/S0392-9590.17.03801-9","article-title":"Clinical efficacy and safety of a new 1000\u2010mg suspension versus twice\u2010daily 500\u2010mg tablets of MPFF in patients with symptomatic chronic venous disorders: a randomized controlled trial","volume":"36","author":"Carpentier","year":"2017","journal-title":"Int Angiol"},{"key":"10.1002\/rth2.12527_bb0350","first-page":"399","article-title":"Clinical acceptability study of once\u2010daily versus twice\u2010daily micronized purified flavonoid fraction in patients with symptomatic chronic venous disease: a randomized controlled trial","volume":"35","author":"Kirienko","year":"2016","journal-title":"Int Angiol"},{"key":"10.1002\/rth2.12527_bb0355","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/0268355594009001s06","article-title":"Chronobiology and clinical activity of Daflon 500 mg in chronic venous insufficiency","volume":"9","author":"Menyhei","year":"1994","journal-title":"Phlebology"},{"key":"10.1002\/rth2.12527_bb0360","first-page":"428","article-title":"Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial","volume":"34","author":"Rabe","year":"2015","journal-title":"Int Angiol"},{"key":"10.1002\/rth2.12527_bb0365","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1177\/0268355513489550","article-title":"Veno\u2010active drugs for chronic venous disease: a randomized, double\u2010blind, placebo\u2010controlled parallel\u2010design trial","volume":"29","author":"Belczak","year":"2014","journal-title":"Phlebology"},{"key":"10.1002\/rth2.12527_bb0370","first-page":"47","article-title":"Surgical correction of varicose vein disease under micronized diosmin protection (results of the Russian multicenter controlled trial DEFANS)","volume":"13","author":"Pokrovsky","year":"2007","journal-title":"Angiol Sosud Khir"},{"issue":"8","key":"10.1002\/rth2.12527_bb0375","first-page":"410","article-title":"Analysis of surgical procedures on the vena saphena magna in the Czech Republic and an effect of Detralex during its stripping","volume":"84","author":"Veverkova","year":"2005","journal-title":"Rozhl Chir"},{"key":"10.1002\/rth2.12527_bb0380","first-page":"24","article-title":"Efficacy of a 6\u2010month treatment with Daflon 500 mg in patients with venous leg ulcers associated with chronic venous insufficiency","volume":"22","author":"Roztocil","year":"2003","journal-title":"Int Angiol"},{"key":"10.1002\/rth2.12527_bb0385","first-page":"107","article-title":"Effectiveness of a micronized purified flavonoid fraction (MPFF) in the healing process of lower limb ulcers. An open multicentre study, controlled and randomized","volume":"49","author":"Glinski","year":"2001","journal-title":"Minerva Cardioangiol"},{"key":"10.1002\/rth2.12527_bb0390","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/000331979704800113","article-title":"Efficacy of Daflon 500 mg in venous leg ulcer healing: a double\u2010blind, randomized, controlled versus placebo trial in 107 patients","volume":"48","author":"Guilhou","year":"1997","journal-title":"Angiology"},{"key":"10.1002\/rth2.12527_bb0395","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/026835559400900206","article-title":"Evaluation of a new venoactive micronized flavonoid fraction (S 5682) in symptomatic disturbances of the venolymphatic circulation of the lower limb: a double\u2010blind, placebo\u2010controlled study","volume":"9","author":"Gilly","year":"1994","journal-title":"Phlebology"},{"key":"10.1002\/rth2.12527_bb0400","first-page":"376","article-title":"Venous insufficiency and Daflon 500 mg [Insuffisance veineuse et Daflon 500 mg]","volume":"IX","author":"Planchon","year":"1990","journal-title":"Art\u00e8res Veines"},{"key":"10.1002\/rth2.12527_bb0405","first-page":"53","article-title":"[On the therapy of so\u2010called leg pains. Controlled double\u2010blind study of the therapeutic efficacy of Daflon]","volume":"11","author":"Biland","year":"1982","journal-title":"Vasa"},{"key":"10.1002\/rth2.12527_bb0410","doi-asserted-by":"crossref","first-page":"79","DOI":"10.23736\/S0392-9590.17.03875-5","article-title":"Use of venoactive drugs after surgery for varicose veins: a preliminary study","volume":"37","author":"Mazzaccaro","year":"2018","journal-title":"Int Angiol"},{"key":"10.1002\/rth2.12527_bb0415","first-page":"77","article-title":"[Effect of pharmacotherapy on course of postoperative period after endovenous thermal ablation]","volume":"21","author":"Stoiko","year":"2015","journal-title":"Angiol Sosud Khir"},{"key":"10.1002\/rth2.12527_bb0420","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1053\/ejvs.2001.1531","article-title":"A randomised controlled trial of micronised purified flavonoid fraction vs placebo in patients with chronic venous disease","volume":"23","author":"Danielsson","year":"2002","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1002\/rth2.12527_bb0425","first-page":"89","article-title":"A double blind, randomized study evaluating the influence of semisynthetic diosmin, and purified, micronized flavonoid fraction (diosmin and hesperidin), on symptoms of chronic venous insufficiency of lower limbs \u2010 a four week observation","volume":"12","author":"Maruszynski","year":"2004","journal-title":"Przeglad Flebologiczny"},{"key":"10.1002\/rth2.12527_bb0430","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/107424840200700303","article-title":"HR (Venoruton1000, Paroven, 0\u2010[beta\u2010hydroxyethyl]\u2010rutosides) vs. Daflon 500 in chronic venous disease and microangiopathy: an independent prospective, controlled, randomized trial","volume":"7","author":"Belcaro","year":"2002","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1002\/rth2.12527_bb0435","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/107602960601200209","article-title":"Comparison of Pycnogenol and Daflon in treating chronic venous insufficiency: a prospective, controlled study","volume":"12","author":"Cesarone","year":"2006","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1002\/rth2.12527_bb0440","doi-asserted-by":"crossref","first-page":"291","DOI":"10.23736\/S0392-9590.19.04216-0","article-title":"Benefits of venoactive drug therapy in surgical or endovenous treatment for varicose veins: a systematic review","volume":"38","author":"Mansilha","year":"2019","journal-title":"Int Angiol"},{"issue":"2","key":"10.1002\/rth2.12527_bb0445","doi-asserted-by":"crossref","first-page":"143","DOI":"10.23736\/S0392-9590.18.03975-5","article-title":"Efficacy of micronized purified flavonoid fraction (Daflon(R)) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta\u2010analysis of randomized double\u2010blind placebo\u2010controlled trials","volume":"37","author":"Kakkos","year":"2018","journal-title":"Int Angiol"},{"key":"10.1002\/rth2.12527_bb0450","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0268355517692221","article-title":"Recommendations for the medical management of chronic venous disease: The role of micronized purified flavanoid fraction (MPFF)","volume":"32","author":"Bush","year":"2017","journal-title":"Phlebology"},{"key":"10.1002\/rth2.12527_bb0455","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/00003495-200363010-00005","article-title":"Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids","volume":"63","author":"Lyseng\u2010Williamson","year":"2003","journal-title":"Drugs"},{"issue":"6","key":"10.1002\/rth2.12527_bb0460","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2165\/00044011-199918060-00001","article-title":"Therapeutic effect of venotonics in chronic venous insufficiency. A meta\u2010analysis","volume":"18","author":"Boada","year":"1999","journal-title":"Drug Investig"},{"key":"10.1002\/rth2.12527_bb0465","first-page":"310","article-title":"Meta\u2010analysis of the impact of the principal venoactive drugs agents on malleolar venous edema","volume":"31","author":"Allaert","year":"2012","journal-title":"Int Angiol"},{"key":"10.1002\/rth2.12527_bb0470","first-page":"309","article-title":"Veno\u2010active drugs in the management of chronic venous disease. An international consensus statement: current medical position, prospective views and final resolution","volume":"33","author":"Ramelet","year":"2005","journal-title":"Clin Hemorheol Microcirc"},{"issue":"4","key":"10.1002\/rth2.12527_bb0475","first-page":"CD003229","article-title":"Phlebotonics for venous insufficiency","volume":"4","author":"Martinez","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1002\/rth2.12527_bb0480","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1177\/0268355515587194","article-title":"Pharmacological adjuncts for chronic venous ulcer healing: a systematic review","volume":"31","author":"Varatharajan","year":"2016","journal-title":"Phlebology"},{"key":"10.1002\/rth2.12527_bb0485","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/0268355512471929","article-title":"Treatment of chronic venous disease with flavonoids: recommendations for treatment and further studies","volume":"28","author":"Rabe","year":"2013","journal-title":"Phlebology"},{"issue":"5","key":"10.1002\/rth2.12527_bb0490","first-page":"CD006477","article-title":"Flavonoids for treating venous leg ulcers","author":"Scallon","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1002\/rth2.12527_bb0495","first-page":"17","article-title":"Venous leg ulcers","volume":"2008","author":"Nelson","year":"2008","journal-title":"BMJ Clin Evid"},{"key":"10.1002\/rth2.12527_bb0500","first-page":"22","article-title":"Etude du d\u00e9lai et de la dur\u00e9e d\u2019action de Daflon 500mg","volume":"88","author":"Amiel","year":"1987","journal-title":"J Int Med"},{"key":"10.1002\/rth2.12527_bb0505","first-page":"88","article-title":"[Phlebotrophic therapy with venarus in patients suffering from lower limb chronic venous insufficiency]","volume":"19","author":"Gudymovich","year":"2013","journal-title":"Angiol Sosud Khir"},{"key":"10.1002\/rth2.12527_bb0510","first-page":"182","article-title":"Benefit of Daflon 500 mg in combination with sclerotherapy of telangiectasias of the lower limbs: results from the SYNERGY and SATISFY surveys","volume":"19","author":"Pitsch","year":"2011","journal-title":"Phlebolymphology"},{"key":"10.1002\/rth2.12527_bb0515","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s12325-018-0849-z","article-title":"Use of micronized purified flavonoid fraction together with rivaroxaban improves clinical and ultrasound outcomes in femoropopliteal venous thrombosis: results of a pilot clinical trial","volume":"36","author":"Lobastov","year":"2019","journal-title":"Adv Ther"},{"key":"10.1002\/rth2.12527_bb0520","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1177\/0268355515619562","article-title":"Pharmacological adjuncts for chronic venous ulcer healing","volume":"31","author":"Coccheri","year":"2016","journal-title":"Phlebology"},{"issue":"suppl 1","key":"10.1002\/rth2.12527_bb0525","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1177\/00033197050560i106","article-title":"Daflon 500 mg and venous leg ulcer: new results from a meta\u2010analysis","volume":"56","author":"Smith","year":"2005","journal-title":"Angiology"},{"key":"10.1002\/rth2.12527_bb0530","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1185\/03007999209111529","article-title":"Therapeutic effects of hidrosmin on chronic venous insufficiency of the lower limbs","volume":"12","author":"Dom\u00ednguez","year":"1992","journal-title":"Curr Med Res Opin"},{"key":"10.1002\/rth2.12527_bb0535","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0011-393X(05)80444-8","article-title":"Therapeutic value of hidrosmin in the treatment of venous disorders of the lower limbs","volume":"52","author":"Fermoso","year":"1992","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1002\/rth2.12527_bb0540","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/000331970005100106","article-title":"Clinical efficacy of micronized purified flavonoid fraction (MPFF) in edema","volume":"51","author":"Olszewski","year":"2000","journal-title":"Angiology"},{"key":"10.1002\/rth2.12527_bb0545","unstructured":"ISRCTN18841175. Effects of micronised purified flavonoic fraction on microcirculation in women suffering from chronic venous disease. http:\/\/www.isrctn.com\/ISRCTN18841175. 2009 (accessed 28 October 2014).."},{"key":"10.1002\/rth2.12527_bb0550","unstructured":"NCT01532882. Efficacy and safety of Diosmin 600mg versus placebo on painful symptomatology in patients with chronic venous disease of lower limbs (EDEN). http:\/\/clinicaltrials.gov\/show\/NCT01532882. 2012 (accessed 28 October 2014)."},{"key":"10.1002\/rth2.12527_bb0555","doi-asserted-by":"crossref","first-page":"NP36","DOI":"10.1177\/0268355517732911","article-title":"Corrigendum","volume":"32","year":"2017","journal-title":"Phlebology"},{"key":"10.1002\/rth2.12527_bb0560","first-page":"306","article-title":"The place of Daflon 500 mg in recent guidelines on the management of chronic venous disease","volume":"33","author":"Pitsch","year":"2011","journal-title":"Medicographia"},{"key":"10.1002\/rth2.12527_bb0565","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000054072","article-title":"Clinical efficacy of micronized purified flavonoid fraction: an overview","volume":"36","author":"Struckmann","year":"1999","journal-title":"J Vasc Res"},{"key":"10.1002\/rth2.12527_bb0570","first-page":"321","article-title":"Management of chronic venous disease: the example of Daflon 500 mg","volume":"16","author":"Ramelet","year":"2009","journal-title":"Phlebolymphology"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rth2.12527","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/rth2.12527","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922013954?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922013954?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rth2.12527","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:23:22Z","timestamp":1762863802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037922013954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":113,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S2475037922013954"],"URL":"https:\/\/doi.org\/10.1002\/rth2.12527","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Micronized purified flavonoid fraction for the treatment of chronic venous insufficiency, with a focus on postthrombotic syndrome: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1002\/rth2.12527","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 The Authors. Research and Practice in Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}],"article-number":"e12527"}}